Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines.

Hossain, Md Jamal; Rabaan, Ali A; Mutair, Abbas Al; Alhumaid, Saad; Emran, Talha Bin; Saikumar, G; Mitra, Saikat; Dhama, Kuldeep

Hossain, Md Jamal; Rabaan, Ali A; Mutair, Abbas Al; Alhumaid, Saad; Emran, Talha Bin; Saikumar, G; Mitra, Saikat; Dhama, Kuldeep.

Afiliación

Hossain MJ; Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh.
Rabaan AA; Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Mutair AA; Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.
Alhumaid S; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Emran TB; Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.
Saikumar G; College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Mitra S; School of Nursing, Wollongong University, Wollongong, NSW, Australia.
Dhama K; Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, Saudi Arabia.

Hum Vaccin Immunother ; 18(1): 2027197, 2022 12 31.

Article en En | MEDLINE | ID: mdl-35172687

Asunto(s)

COVID-19; SARS-CoV-2; COVID-19/prevención & control; Vacunas contra la COVID-19; Genómica; Humanos; SARS-CoV-2/genética

Palabras clave

Mu variant; SARS-CoV-2 B.1.621; genomic surveillance; global mass vaccination; non-pharmaceutical interventions (NPIs); sub-lineage B.1.621.1; vaccine breakthrough

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2022 Tipo del documento: Article País de afiliación: Bangladesh Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google